Phase lb combination trial of a MEK inhibitor, pimasertib (MSC1936369B), and a PI3K/mTOR inhibitor, SAR245409, in patients with locally advanced or metastatic solid tumors

被引：0
|
作者：
Infante, Jeffrey R.
Gandhi, Leena
Shapiro, Geoffrey
Burris, Howard A.
Bendell, Johanna C.
Baselga, Jose
Hsu, Karl
Faivre, Thea
Asatiani, Ekatherine
Heist, Rebecca Suk
机构：
[1] Sarah Cannon Res Inst, Nashville, TN USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Massachusetts Gen Hosp, Boston, MA 02114 USA
[4] Sanofi, Cambridge, MA USA
[5] Merck Serono SA, Geneva, Switzerland
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS3118
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A phase 1 trial of the MEK inhibitor selumetinib in combination with pembrolizumab for advanced or metastatic solid tumors
    Chenard-Poirier, Maxime
    Hansen, Aaron R.
    Gutierrez, Martin E.
    Rasco, Drew
    Xing, Yan
    Chen, Lin-Chi
    Zhou, Heng
    Webber, Andrea L.
    Freshwater, Tomoko
    Sharma, Manish R.
    INVESTIGATIONAL NEW DRUGS, 2024, 42 (03) : 241 - 251
  • [22] Phase Ib trial of the PI3K/mTOR inhibitor voxtalisib (SAR245409) in combination with chemoimmunotherapy in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma, mantle cell lymphoma, or chronic lymphocytic leukemia
    Awan, Farrukh
    Gore, Lia
    Gao, Lei
    Lager, Joanne
    Costa, Luciano
    LEUKEMIA & LYMPHOMA, 2015, 56 : 18 - 18
  • [23] A Phase I Dose Expansion Cohort Study of the Safety, Pharmacokinetics and Pharmacodynamics of SAR245409 (S09), An Orally Administered PI3K/mTOR Inhibitor, in Patients with Lymphoma
    Papadopoulos, Kyriakos P.
    Abrisqueta, Pau
    Chambers, Glenda
    Rasco, Drew
    Patnaik, Amita
    Tabernero, Josep
    Rajangam, Kanya
    Rockich, Kevin
    Egile, Coumaran
    Kelly, Adrianne
    Xu, Yi
    Lager, Joanne
    Vose, Julie M.
    BLOOD, 2011, 118 (21) : 699 - 699
  • [24] PHASE I/II STUDY OF FOLFIRI PLUS THE MEK1/2 INHIBITOR PIMASERTIB (MSC1936369B) AS SECOND-LINE TREATMENT FOR KRAS MUTATED METASTATIC COLORECTAL CANCER
    Macarulla, Teresa
    Tabernero, Josep
    Cervantes, Andres
    Rosello, Susana
    Van Cutsem, Eric
    Tejpar, Sabine
    Prenen, Hans
    Martinelli, Erika
    Troiani, Teresa
    Campana, Fank
    Laffranchi, Bernard
    Jego, Virginie
    von Richter, Oliver
    Ciardiello, Fortunato
    ANNALS OF ONCOLOGY, 2012, 23 : 27 - 27
  • [25] Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors
    Geoffrey I. Shapiro
    Patricia LoRusso
    Eunice Kwak
    Susan Pandya
    Charles M. Rudin
    Carla Kurkjian
    James M. Cleary
    Mary Jo Pilat
    Suzanne Jones
    Alex de Crespigny
    Jill Fredrickson
    Luna Musib
    Yibing Yan
    Matthew Wongchenko
    Hsin-Ju Hsieh
    Mary R. Gates
    Iris T. Chan
    Johanna Bendell
    Investigational New Drugs, 2020, 38 : 419 - 432
  • [26] Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors
    Shapiro, Geoffrey, I
    LoRusso, Patricia
    Kwak, Eunice
    Pandya, Susan
    Rudin, Charles M.
    Kurkjian, Carla
    Cleary, James M.
    Pilat, Mary Jo
    Jones, Suzanne
    de Crespigny, Alex
    Fredrickson, Jill
    Musib, Luna
    Yan, Yibing
    Wongchenko, Matthew
    Hsieh, Hsin-Ju
    Gates, Mary R.
    Chan, Iris T.
    Bendell, Johanna
    INVESTIGATIONAL NEW DRUGS, 2020, 38 (02) : 419 - 432
  • [27] Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer
    Ramanathan, Ramesh K.
    Von Hoff, Daniel D.
    Eskens, Ferry
    Blumenschein, George, Jr.
    Richards, Donald
    Genvresse, Isabelle
    Reschke, Susanne
    Granvil, Camille
    Skubala, Adam
    Pena, Carol
    Mross, Klaus
    TARGETED ONCOLOGY, 2020, 15 (02) : 163 - 174
  • [28] Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer
    Ramesh K. Ramanathan
    Daniel D. Von Hoff
    Ferry Eskens
    George Blumenschein
    Donald Richards
    Isabelle Genvresse
    Susanne Reschke
    Camille Granvil
    Adam Skubala
    Carol Peña
    Klaus Mross
    Targeted Oncology, 2020, 15 : 163 - 174
  • [29] First-in-Human Trial of the PI3Kβ-Selective Inhibitor SAR260301 in Patients With Advanced Solid Tumors
    Bedard, Philippe L.
    Davies, Michael A.
    Kopetz, Scott
    Juric, Dejan
    Shapiro, Geoffrey I.
    Luke, Jason J.
    Spreafico, Anna
    Wu, Bin
    Castell, Christelle
    Gomez, Corinne
    Cartot-Cotton, Sylvaine
    Mazuir, Florent
    Dubar, Michel
    Micallef, Sandrine
    Demers, Brigitte
    Flaherty, Keith T.
    CANCER, 2018, 124 (02) : 315 - 324
  • [30] Selective Oral MEK1/2 Inhibitor Pimasertib: A Phase I Trial in Patients with Advanced Solid Tumors
    Delord, Jean-Pierre
    Italiano, Antoine
    Awada, Ahmad
    Aftimos, Philippe
    Houede, Nadine
    Lebbe, Celeste
    Pages, Celine
    Lesimple, Thierry
    Dinulescu, Monica
    Schellens, Jan H. M.
    Leijen, Suzanne
    Rottey, Sylvie
    Kruse, Vibeke
    Kefford, Richard
    Faivre, Sandrine
    Gomez-Roca, Carlos
    Scheuler, Armin
    Massimini, Giorgio
    Raymond, Eric
    TARGETED ONCOLOGY, 2021, 16 (01) : 37 - 46
12345